We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Staying fit

1 February 2019 By Neil Unmack

Strong sales of drugs to combat diabetes and obesity boosted the Danish drug company’s shares. But the rising number of users could give U.S. health providers scope to negotiate cheaper prices. The arrival of rival medicines, and expiring patents may give them leverage.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)